Letters to the Editor

• Is the Evidence Provided by the SPRINT Trial Solid Enough to Support a Systolic Blood Pressure Threshold of 120 mmHg?

  Sebastián García-Zamora, Fernando Botto

  Rev Esp Cardiol. 2019;72:520-1

• 3D Printing in Revista Española de Cardiología: Just a Passing Fad?

  Gorka Gomez, Israel Valverde

  Rev Esp Cardiol. 2019;72:275

• Antiarrhythmic Drugs Are not the Only Option in Electrical Storm: Extracorporeal Membrane Oxygenation as a Life-saving Alternative. Response

  Jorge García Carreño, Iago Sousa-Casasnovas, Francisco Fernández Avilés, Manuel Martínez Sellés

  Rev Esp Cardiol. 2019;72:185

• Antiarrhythmic Drugs Are not the Only Option in Electrical Storm: Extracorporeal Membrane Oxygenation as a Life-saving Alternative

  Raphaël P. Martins, Erwan Flecher, Solène Le Pennec-Prigent, Vincent Galand

  Rev Esp Cardiol. 2019;72:184

• Use of High-potency Statins After Percutaneous Revascularization

  Mercedes Millán Gómez, Macarena Cano García, Carlos Sánchez González, Manuel Jiménez Navarro

  Rev Esp Cardiol. 2019;72:98

• Prophylaxis of Infective Endocarditis in Dentistry: Analysis of the Situation After Almost a Decade of Clinical Practice Guidelines

  Iria Silva Conde, Francisco Torres-Saura, Alberto Alperi García, Jesús María de la Hera Galarza

  Rev Esp Cardiol. 2019;72:95

• Prophylaxis of Infective Endocarditis in Dentistry: Analysis of the Situation After Almost a Decade of Clinical Practice Guidelines. Response

  Paula Anguita, Juan C. Castillo, Manuela Herrera, Manuel Anguita

  Rev Esp Cardiol. 2019;72:96

• Use of Oral Anticoagulation for Patients With Atrial Fibrillation and End-stage Renal Disease: What Is Needed Nowadays?

  Jun Li, Xinyue Liu, Sulin Zheng, Yuli Huang

  Rev Esp Cardiol. 2019;72:96-7

• Use of Oral Anticoagulation in Patients With Atrial Fibrillation and End-stage Renal Disease: What Is Needed Nowadays? Response

  Maria Mahmood, Gregory Y.H. Lip

  Rev Esp Cardiol. 2019;72:97-8

• Cost-effectiveness of Evolocumab

  Carlos Escobar, Vivencio Barrios

  Rev Esp Cardiol. 2018;71:1089

• Cost-effectiveness of Evolocumab. Response

  Antonio Olry de Labry Lima, Antonio Matas Hoces, Emilio Jesús Alegre del Rey, Vicente Gimeno Ballester

  Rev Esp Cardiol. 2018;71:1090

• Cancer and Acute Coronary Syndrome. A Close but Complicated Relationship

  Gerard Oristrell

  Rev Esp Cardiol. 2018;71:879-80

• Cancer and Acute Coronary Syndrome. A Close, but Complicated Relationship. Response

  Alberto Cordero, Vicente Bertomeu-González, Julio Núñez, Vicente Bertomeu-Martínez

  Rev Esp Cardiol. 2018;71:880-1

• Antithrombotic Therapy and Surgery: From Consensus to Clinical Practice. Response to Related Letters

  David Vivas, Jose Luis Ferreiro, Inmaculada Roldán

  Rev Esp Cardiol. 2018;71:879

• Antiplatelet Bridging Is an Option During Perioperative and Periprocedural Management of Antithrombotic Therapy

  Santiago de Dios

  Rev Esp Cardiol. 2018;71:877

• Management of Anticoagulants in Procedures That Can Cause Bleeding

  Enrique Martín-Rioboó, Cristina Martín-Mañero, Paula Medina-Durán, Luis Angel Pérula-de Torres

  Rev Esp Cardiol. 2018;71:878

• Phenotype-modifying Factors in Hypertrophic Cardiomyopathy

  Javier Limeres Freire

  Rev Esp Cardiol. 2018;71:770

• Phenotype-modifying Factors in Hypertrophic Cardiomyopathy. Response

  Inmaculada Pérez-Sánchez, María Sabater-Molina, Carmen Muñoz-Esparza, Juan Ramón Gimeno-Blanes

  Rev Esp Cardiol. 2018;71:770-1

• Soria Cardioprotegida. The First Spanish Program for the Prevention and Integral Treatment of Sudden Cardiac Death

  Juan Ruiz-García, Irene Canal-Fontcuberta, Alberto Caballero-García, Juan Manuel Ruiz-Liso

  Rev Esp Cardiol. 2018;71:689

• Soria Cardioprotegida. The First Spanish Program for the Prevention and Integral Treatment of Sudden Cardiac Death. Response

  Pablo Loma-Osorio, Ramon Brugada

  Rev Esp Cardiol. 2018;71:690